Researchers may have discovered the reason that immunotherapy drugs work miracles on some mesothelioma patients and have no effect on others. Doctors have tried to tackle this problem from every angle they could think of and now there’s a new focus: the gut.
Recent studies show that one of the major factors in immune response is intestinal microbiota, or gut microbes. Over the past few years researchers have been tracking the connections between gut bacteria and cancer to try to create new treatments for cancers like mesothelioma.
Gut Microbes and Immunotherapy
A leading research journal, Science, recently published the findings of an experiment performed by Dr. Gajewski and his team at the University of Chicago. Their goal was to explain why some patients have a stronger immune response to cancer than others.
The team experimented using two sets of mice with different gut microbes. One set was purchased from Jackson Laboratory (JAX) and one set from Taconic Biosciences (TAC). When the researchers studied them separately, the TAC mice developed more aggressive tumors than the JAX mice. The JAX mice had a stronger immune response against the cancer, helping them to fight off the disease.
However, when the mice were kept together, they all had similar responses. The somewhat gross reason for this: mice eat each other’s feces. When the TAC mice ate the JAX feces they gained the microbes that JAX mice had in their intestines.
Immunotherapy and Mesothelioma
For mesothelioma patients, one of the most promising new treatment options are immunotherapy drugs. These drugs channel a patient’s own immune system to fight off the mesothelioma in their body. Usually this results in fewer side effects than traditional cancer treatments because the immune system can target only specific cells.
Keytruda (pembrolizumab) was developed by the global healthcare company, Merck. It is an anti-PD-L1 drug that has been shown to improve a mesothelioma patient’s prognosis. PD-L1 is a protein in some people’s bodies that suppresses their immune system. Keytruda works to block PD-L1, allowing the immune system to have a greater response against the cancer cells.
Keytruda is currently being tested to treat mesothelioma in clinical trials at the University of Chicago.
The Future of Gut Microbes and Immunotherapy
In the case of the mice, researchers saw similar improvement in the mice that were treated with Bifs as with the mice that were treated with an anti-PD-L1 drug. They then tried combining the two treatments. By making sure the mice had the best gut microbes to fight cancer and then adding an immunotherapy drug, the researcher saw even more encouraging results.